

PUBLICATIONS 2024 BBE – Gustave Roussy

BUREAU DE BIOSTATISTIQUE ET D'EPIDEMIOLOGIE

BIOSTATISTICS AND EPIDEMIOLOGY DEPARTMENT

1. Ben-Ammar I, **Rousseau A**, Nicolle R, Tarabay A, Boige V, Valery M, Pudlarz T, Malka D, Gelli M, Fernandez-De-Sevilla E, Fuerea A, **Tanguy ML**, Rouleau E, Barbe R, Mathieu JRR, Jaulin F, Smolenschi C, Hollebecque A, Ducreux M, Boileve A.
Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
European Journal of Cancer. 2024 Jan;197:113497.
doi: 10.1016/j.ejca.2023.113497. Epub 2023 Dec 15. PMID: 38134480
2. Leon-Ferre RA, **Jonas SF**, Salgado R, Loi S, de Jong V, Carter JM, Nielsen TO, Leung S, Riaz N, Chia S, Jules-Clément G, Curigliano G, Criscitiello C, Cockenpot V, Lambertini M, Suman VJ, Linderholm B, Martens JWM, van Deurzen CHM, Timmermans AM, Shimo T, Yazaki S, Yoshida M, Kim SB, Lee HJ, Dieci MV, Bataillon G, Vincent-Salomon A, André F, Kok M, Linn SC, Goetz MP, **Michiels S**; International Immuno-Oncology Biomarker Working Group.
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
JAMA. 2024 Apr 2;331(13):1135-1144. doi: 10.1001/jama.2024.3056.
PMID: 38563834
3. André F, Rassy E, Marabelle A, **Michiels S**, Besse B.
Forget lung, breast or prostate cancer: why tumour naming needs to change.
Nature 2024 Feb;626(7997):26-29. doi: 10.1038/d41586-024-00216-3.
PMID: 38347121

4. Jahangir CA, Page DB, Broeckx G, Gonzalez CA, Burke C, Murphy C, Reis-Filho JS, Ly A, Harms PW, Gupta RR, Vieth M, Hida AI, Kahila M, Kos Z, van Diest PJ, Verbandt S, Thagaard J, Khiraya R, Abduljabbar K, Acosta Haab G, Acs B, Adams S, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, Baharun NB, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Burgues O, Chardas A, Cheang MCU, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dantas Portela FL, Deman F, Demaria S, Dudgeon SN, Elghazawy M, Fernandez-Martín C, Fineberg S, Fox SB, Giltane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hart SN, Hartman J, Hewitt S, Horlings HM, Husain Z, Irshad S, Janssen EA, Kataoka TR, Kawaguchi K, Khrantsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Akturk G, Scott E, Kovács A, Laenholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, **Michiels S**, Kharidehal D, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rajpoot NM, Rapoport BL, Rau TT, Ribeiro JM, Rimm D, Vincent-Salomon A, Saltz J, Sayed S, Hytopoulos E, Mahon S, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Aubrey Thompson E, Tramm T, T Tran W, Van der Laak J, E Verghese G, Viale G, Wahab N, Walter T, Waumans Y, Y Wen H, Yang W, Yuan Y, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Specht Stovgaard E, Salgado R, M Gallagher W, Rahman A.
Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer. The Journal of Pathology. 2024 Mar;262(3):271-288. doi: 10.1002/path.6238. Epub 2024 Jan 17. PMID: 38230434
5. Bottosso M, Mosele F, **Michiels S**, Cournède P-H, Dogan S, Labaki C, André F. Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer. ESMO Open. 2024 Mar;9(3):102247. doi: 10.1016/j.esmoop.2024.102247. Epub 2024 Feb 23. PMID: 38401248
6. Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, **Bayle A**, Bièche I, **Bonastre J**, Castro E, Dienstmann R, Krämer A, Czarnecka AM, Meric-Bernstam F, **Michiels S**, Miller R, Normanno N, Reis-Filho J, Remon J, Robson M, Rouleau E, Scarpa A, Serrano C, Mateo J, André F.
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. 2024 Jul;35(7):588-606. doi: 10.1016/j.annonc.2024.04.005. Epub 2024 May 27. PMID: 38834388

7. Vasseur D, Arbab A, **Giudici F**, Marzac C, **Michiels S**, Tagliamento M, **Bayle A**, Smolenschi C, Sakkal M, Aldea M, Sassi H, Dall'Olio FG, Pata-Merci N, Cotteret S, Fiévet A, Auger N, Friboulet L, Facchinetti F, Géraud A, Ponce S, Hollebecque A, Besse B, Micol JB, Italiano A, Lacroix L, Rouleau E.
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients. NPJ Precision Oncology. 2024 Feb 26;8(1):51.
doi: 10.1038/s41698-024-00544-7. PMID: 38409229

8. Franzoi MA, Di Meglio A, **Michiels S**, Gillanders E, Gaudin C, Martin AL, Vaz-Luis I.
Patient-Reported Quality of Life 6 Years After Breast Cancer.
JAMA Network Open. 2024 Feb 5;7(2):e240688.
doi: 10.1001/jamanetworkopen.2024.0688. PMID: 38421653

9. Soldato D, **Michiels S**, Havas J, Di Meglio A, Pagliuca M, Franzoi MA, Pistilli B, Iyengar NM, Cottu P, Lerebours F, Coutant C, Bertaut A, Tredan O, Vanlemmens L, Jouannaud C, Hrab I, Everhard S, Martin AL, André F, Vaz-Luis I, Jones LW.
Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer. Journal of Clinical Oncology. 2024 Sep 1;42(25):3022-3032.
doi: 10.1200/JCO.23.01959. Epub 2024 Jun 5. PMID: 38838281

10. Geurts VCM, Balduzzi S, Steenbruggen TG, Linn SC, Siesling S, Badve SS, DeMichele A, Ignatiadis M, Leon-Ferre RA, Goetz MP, Wolff AC, Klar N, **Michiels S**, Loi S, Adams S, Horlings HM, Sonke GS, Salgado R, Kok M.
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy. JAMA Oncology.
2024 Aug 1;10(8):1077-1086. doi: 10.1001/jamaoncol.2024.1917.
PMID: 38935352

11. Chaix J, Schleiermacher G, Corradini N, André N, Thebaud E, Gambart M, Defachelles AS, Entz-Werle N, Chastagner P, De Carli É, Ducassou S, Landman-Parker J, Adam-de-Baumais T, **Larive A**, **Michiels S**, Vassal G, Valteau-Couanet D, Geoerger B, Berlanga P.
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.
European Journal of Cancer. 2024 Apr;201:113923.
doi: 10.1016/j.ejca.2024.113923. Epub 2024 Feb 15. PMID: 38377775

12. Ba MB, **Giudici F**, Bellini C, Auzac G, Louvel G, Bockel S, Moukasse Y, Chaffai I, Berthelot K, Vatonne A, Conversano A, Viansone A, Larue C, Deutsch E, **Michiels S**, Milewski C, Rivera S.
Feasibility and Safety of the "One-Week Breast Radiation Therapy" Program. Clinical oncology (Royal College of Radiologists (Great Britain)). 2024 Sep;36(9):e333-e341. doi: 10.1016/j.clon.2024.06.045. Epub 2024 Jun 15. PMID: 38971686
13. Courtinard C, Barbet V, Schiappa R, Pilleul F, **Michiels S**, Dabakuyo S, Gourgou S, Jaffre A, Asselain B, Bosquet L, Dunton K, Rosenlund M, Liang A, Cathcart J, Delaloge S.
Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: a multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018). ESMO Real World Data and Digital Oncology. doi : 10.1016/j.esmorw.2024.100043
14. Roblin E, Cournède P-H, **Michiels S**
Confidence intervals of survival predictions with neural networks trained on molecular data. Informatics in Medicine Unlocked. doi: 10.1016/j.imu.2023.101426
15. **Hill C**.
[Trends in the frequency of cancer in France]. Bulletin du Cancer. 2024 Jan;111(1):33-36. doi: 10.1016/j.bulcan.2023.09.007. Epub 2023 Oct 17. PMID: 37858423
16. Gueiderikh A, Tarabay A, **Abdelouahab M**, Smolenschi C, **Tanguy ML**, Valery M, Malka D, Pudlarz T, Fuerea A, Boige V, Hollebecque A, Ducreux M, Boilève A.
Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study. BMC Cancer. 2024 Feb 26;24(1):272. doi: 10.1186/s12885-024-12016-z. PMID: 38408958
17. Guigay J, Ortholan C, Vansteene D, Cupissol D, Even C, Kaminsky MC, Sire C, Blot E, Debourdeau P, Bozec L, Saada-Bouzid E, Fayette J, Dalloz P, Pointreau Y, Caer HL, Falandry C, Digue L, Braccini A, Lopez S, Guillet P, Michel C, Cheurfa N, Schwob D, Bourhis J, Mertens C, **Aupérin A**; ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups and the GORTEC.
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial. The Lancet Healthy longevity. 2024 Mar;5(3):e182-e193. doi: 10.1016/S2666-7568(23)00284-2. PMID: 38432247

18. Abbaci M, Villard A, **Auperin A**, Asmandar S, Moya-Plana A, Casiraghi O, Breuskin I.
Ultra-fast confocal fluorescence microscopy for neck lymph node imaging in head and neck cancer. Oral Oncology. 2024 Jul;154:106862.
doi: 10.1016/j.oraloncology.2024.106862. Epub 2024 May 30. PMID: 38820885
19. Guigay J, Le Caer H, Ferrand FR, Geoffrois L, Saada-Bouazid E, Fayette J, Sire C, Cupissol D, Blot E, Guillet P, Pavillet J, Bozec L, Capitain O, Rolland F, Debourdeau P, Pointreau Y, Falandry C, Lopez S, Coutte A, Chatellier T, Dalloz P, Ortholan C, Michel C, **Lacas B**, Cheurfa N, Schwob D, Bourhis J, Mertens C, **Aupérin A**; ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups, and GORTEC.
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial. The lancet Healthy longevity. 2024 Jun;5(6):e392-e405. doi: 10.1016/S2666-7568(24)00048-5.
Epub 2024 May 14. PMID: 38759667
20. Lueza B, **Aupérin A**, Rigaud C, Gross TG, Pillon M, Delgado RF, Uyttebroeck A, Amos Burke GA, Zsíros J, Csóka M, Simonin M, Patte C, Minard-Colin V, **Bonastre J**.
Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphoma.
The European Journal of Health Economics. 2024 Mar;25(2):307-317.
doi: 10.1007/s10198-023-01581-y. Epub 2023 Apr 14. PMID: 37058173
21. Limkin E, Blanchard P, **Lacas B**, Bourhis J, Parmar M, Licitra L, Le QT, Yom SS, Fortpied C, Langendijk J, Vermorken JB, Bernier J, Overgaard J, Harris J, **Pignon JP**, **Auperin A**; MACH-NC* and MARCH** collaborative groups.
Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses. Radiotherapy and oncology. 2024 Jan;190:110011. doi:10.1016/j.radonc.2023.110011. Epub 2023 Nov 11. PMID: 37956890
22. Mirghani H, Tendron A, **Auperin A**, Casiraghi O, Classe M, Badoual C, **Legoupil C**, Puech J, Veyer D, Dalstein V, Pere H, Gorphe P.
HPV-driven oropharyngeal cancer burden in Paris and its region (ILE DE FRANCE) from 1981 TO 2021. Cancer Epidemiology. 2024 Aug;91:102603.
doi: 10.1016/j.canep.2024.102603. Epub 2024 Jun 19. PMID: 38901087

23. de Jager VD, Timens W, **Bayle A**, Botling J, Brcic L, Büttner R, Fernandes MGO, Havel L, Hochmair M, Hofman P, Janssens A, van Kempen L, Kern I, Machado JC, Mohorčič K, Popat S, Ryška A, Wolf J, Schuuring E, van der Wekken AJ. Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer. The Lancet Regional Health. Europe. 2024 Mar 1;38:100839. doi: 10.1016/j.lanepe.2024.100839. eCollection 2024 Mar. PMID: 38476751
24. de Jager VD, Timens W, **Bayle A**, Botling J, Brcic L, Büttner R, Fernandes MGO, Havel L, Hochmair MJ, Hofman P, Janssens A, Johansson M, van Kempen L, Kern I, Lopez-Rios F, Lüchtenborg M, Machado JC, Mohorcic K, Paz-Ares L, Popat S, Ryška A, Tanieri P, Wolf J, Schuuring E, van der Wekken AJ. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries. The Lancet Regional Health. Europe. 2024 Mar 1;38:100838. doi: 10.1016/j.lanepe.2024.100838. eCollection 2024 Mar. PMID: 38476742
25. **Bayle A**, Marino P, Baffert S, Margier J, **Bonastre J**. [Cost of high-throughput sequencing (NGS) technologies: Literature review and insights]. [Article in French]. Bulletin du cancer. 2024 Feb;111(2):190-198. doi: 10.1016/j.bulcan.2023.08.013. Epub 2023 Oct 16. PMID: 37852801
26. Lemaitre F, Florentin V, Blin O, **Bayle A**, Benito S, Chauny JV, Galaup A, Korchagina D, Lang M, Le Tourneau C, Pelloux H, Picard N, Guilhaumou R. Can precision medicine be integrated into routine therapeutic decisions at the bedside of patients? Therapie. 2024 Jan-Feb;79(1):13-22. doi: 10.1016/j.therap.2023.11.007. Epub 2023 Dec 1. PMID: 38065821
27. Blanc-Durand F, Camilleri GM, **Bayle A**, Aldea M, Vasseur D, Ouali K, Michels J, Pautier P, Nicotra C, Ngo-Camus M, Lacroix L, Rouleau E, Ponce-Aix S, Italiano A, Leary A. Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer. Cancer. 2024 Oct 1;130(19):3311-3320. doi: 10.1002/cncr.35381. Epub 2024 Jun 2. PMID: 38824658
28. Rodriguez J, Baldini C, **Bayle A**, **Pages A**, Danlos FX, Vasseur D, Rouleau E, Lacroix L, Alonso de Castro B, Goldschmidt V, Seknazi L, Hollebecque A, Michot JM, Champiat S, Marabelle A, Ouali K, Marzac C, Ponce S, Micol JB, Chaput N, Massard C, Italiano A. Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial. JCO Precision Oncology. 2024 May;8:e2300631. doi: 10.1200/PO.23.00631. PMID: 38815178

29. **Bayle A, Chaltiel D**, Latino N, Rouleau E, Peters S, Galotti M, Bricalli G, Besse B, Giuliani R, **Bonastre J**.
Reply to the Letter to the Editor regarding 'Overcoming Barriers in Biomarker Testing' J. García-Foncillas et al. *Annals of oncology*. 2024 Sep;35(9):829-830. doi: 10.1016/j.annonc.2024.05.545. Epub 2024 Jun 6. PMID: 38851588
30. Farah L, **Borget I**, Martelli N, Vallee A.
Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review.
Journal of Medical Internet Research. 2024 May 13;26:e51514. doi: 10.2196/51514. PMID: 38739911
31. Gourdy P, Darmon P, **Borget I**, Emery C, Bureau I, Detournay B, Bahloul A, Allali N, Mahieu A, Penfornis A.
Basal Insulinotherapy in Patients Living with Diabetes in France: The EF-BI Study. *Diabetes Therapy*. 2024 Jun;15(6):1349-1360. doi: 10.1007/s13300-024-01577-8. Epub 2024 Apr 20. PMID: 38642261
32. Martin T, Rioufol C, Favier B, Martelli N, Madelaine I, Chouaid C, **Borget I**.
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs. *BioDrugs*. 2024 May;38(3):465-475. doi: 10.1007/s40259-024-00658-1. Epub 2024 Apr 20. PMID: 38643301
33. Grumberg V, Cotté FE, Giroux-Leprieur E, Gaudin AF, Lebbé C, **Borget I**.
Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021. *ESMO Open*. 2024 Feb;9(2):102240. doi: 10.1016/j.esmoop.2024.102240. Epub 2024 Feb 9. PMID: 38335904
34. Gourdy P, Darmon P, **Borget I**, Emery C, Bureau I, Detournay B, Bahloul A, Allali N, Mahieu A, Penfornis A.
Correction to: Basal Insulinotherapy in Patients Living with Diabetes in France: The EF-BI Study. *Diabetes Therapy*. 2024 Sep;15(9):2131-2132. doi: 10.1007/s13300-024-01621-7. PMID: 39008238

35. **Le Teuff G, Cozic N**, Boyer JC, Boige V, Diasio RB, Taieb J, Meulendijks D, Palles C, Schwab M, Deenen M, Largiadèr CR, Marinaki A, Jennings BA, Wettergren Y, Di Paolo A, Gross E, Budai B, Ackland SP, van Kuilenburg ABP, McLeod HL, Milano G, Thomas F, Lorient MA, Kerr D, Schellens JHM, Laurent-Puig P, Shi Q, **Pignon JP**, Etienne-Grimaldi MC; FUSAFE collaborative group. Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis. *British Journal of Cancer*. 2024 Mar;130(5):808-818. doi: 10.1038/s41416-023-02517-2. Epub 2024 Jan 15. PMID: 38225422
36. Bastard P, **Cozic N**, Brion R, Gaspar N, Piperno-Neumann S, Cordero C, Leculée-Thébaud E, Gomez-Mascard A, Rédini F, Marchais A, Ikononova R, Cleirec M, Laurence V, Rigaud C, **Abbas R**, Verrecchia F, Brugières L, Minard-Colin V. Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience. *Pediatric Blood & Cancer*. 2024 Jul;71(7):e31029. doi: 10.1002/pbc.31029. Epub 2024 Apr 28. PMID: 38679845
37. Alves Costa Silva C, Piccinno G, Suissa D, Bourgin M, Schreiber G, Durand S, Birebent R, Fidelle M, Sow C, Aprahamian F, Manghi P, Punčochář M, Asnicar F, Pinto F, Armanini F, Terrisse S, Routy B, **Drubay D**, Eggermont AMM, Kroemer G, Segata N, Zitvogel L, Derosa L, Bol KF, de Vries IJM. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial. *Nature communications*. 2024 Feb 23;15(1):1633. doi: 10.1038/s41467-024-45357-1. PMID: 38395948
38. Audinot B, **Drubay D**, Gaspar N, Mohr A, Cordero C, Marec-Bérard P, Lervat C, Piperno-Neumann S, Jimenez M, Mansuy L, Castex MP, Revon-Riviere G, Marie-Cardine A, Berger C, Piguet C, Massau K, Job B, Moquin-Beaudry G, Le Deley MC, Tabone MD, Berlanga P, Brugières L, D Crompton B, Marchais A, Abbou S. ctDNA quantification improves estimation of outcomes in patients with high grade osteosarcoma: a translational study from the OS2006 trial. *Annals of oncology*. 2024 Jun;35(6):559-568. doi: 10.1016/j.annonc.2023.12.006. Epub 2023 Dec 22. PMID: 38142939
39. Thuilliez C, Moquin-Beaudry G, Khneisser P, Marques Da Costa ME, Karkar S, Boudhouche H, **Drubay D**, Audinot B, Geoerger B, Scoazec JY, Gaspar N, Marchais A. CellsFromSpace: a fast, accurate, and reference-free tool to deconvolve and annotate spatially distributed omics data. *Bioinformatics advances*. 2024 May 30;4(1):vbae081. doi: 10.1093/bioadv/vbae081. eCollection 2024. PMID: 38915885

40. Colomba E, **Jonas SF**, Eymard JC, Delva R, Brachet PE, Neuzillet Y, Penel N, Roubaud G, Bompas E, Mahammedi H, Longo R, Helissey C, Barthélemy P, Borchellini D, Hasbini A, Priou F, Saldana C, Voog E, Narcisso B, Ladoire S, Berdah JF, Aisenfarb JB, **Foulon S**, Fizazi K.
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA. *European Urology*. 2024 Mar;85(3):274-282.
doi: 10.1016/j.eururo.2023.05.009. Epub 2023 Jun 2. PMID: 37271630
41. Flippot R, Telli T, Velez M, Fléchon A, De Vries-Brilland M, Turpin L, Bergman A, Turco F, Mahammedi H, Fendler WP, Giraudet AL, Josset Q, Montravers F, Vogel W, Gillessen S, Berardi Vilei S, Herrmann K, Kryza D, Paone G, Hadaschik B, Merlin C, Dufour PA, Bernard-Tessier A, Naoun N, Patrikidou A, Garcia C, **Foulon S**, **Pagès A**, Fizazi K.
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.
European Urology Oncology. 2024 Oct;7(5):1132-1140.
doi: 10.1016/j.euo.2024.03.013. Epub 2024 Apr 24. PMID: 38664139
42. **Hill C**.
[Pollution attributable mortality]. [Article in French]. *La Revue du Praticien*. 2024 May;74(5):481-484. PMID: 38833222
43. **Hill C**.
Alcohol in France: room for improvement. *Lancet Public Health*. 2024 Jul;9(7):e416-e417. doi: 10.1016/S2468-2667(24)00124-5. PMID: 38942549
44. Hoffman RM, Brummel S, Ziemba L, Chinula L, McCarthy K, Fairlie L, Jean-Philippe P, Chakhtoura N, Johnston B, Krotje C, Nematadzira TG, Nakayiwa F, Ndyababangi V, Hanley S, Theron G, Violari A, João E, Correa MD Jr, Hofer CB, Navanukroh O, Aupibul L, Nevrekar N, Zash R, Shapiro R, Stringer JSA, Currier JS, Sax P, Lockman S; **IMPAACT 2010/VESTED Study Team**.
Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum. *Clinical Infectious Diseases*. 2024 Jun 14;78(6):1617-1628. doi: 10.1093/cid/ciae001. PMID: 38180851
45. **Hill C**.
[Health effects of alcohol: untangling the truth from the false!]. [Article in French]. *La Revue du Praticien*. 2024 Jun;74(6):594-598. PMID: 39011689

46. **Hill C.**
Comment on "Association between Residential Proximity to Viticultural Areas and Childhood Acute Leukemia Risk in Mainland France: GEOCAP Case-Control Study, 2006-2013". Environmental health perspectives. 2024 Jan;132(1):18001. doi: 10.1289/EHP14230. Epub 2024 Jan 11. PMID: 38206768
47. Kastrisiou M, **Karimi M**, Christou EA, Bizot A, Ropers MA, De-Jesus A, Mokdad-Adi M, To THV, Viansone A, Delaloge S, Besse B, Kfoury M.
Evaluation of the satisfaction and experiences of oncology patients and doctors using teleconsultation during the COVID-19 pandemic.
Journal of Telemedicine and Telecare. 2024 Feb 7:1357633X241229462. doi: 10.1177/1357633X241229462. Online ahead of print. PMID: 38327172
48. Bruschi M, Midjek L, Ajilil Y, Vairy S, Lancien M, Ghermaoui S, Kergrohen T, Verreault M, Idbaih A, de Biagi CAO Junior, Liu I, Filbin MG, Beccaria K, Blauwblomme T, Puget S, Tauziède-Espariat A, Varlet P, Dangouloff-Ros V, Boddaert N, **Le Teuff G**, Grill J, Montagnac G, Elkhatib N, Debily MA, Castel D.
Diffuse midline glioma invasion and metastasis rely on cell-autonomous signaling. Neuro-oncology. 2024 Mar 4;26(3):553-568. doi: 10.1093/neuonc/noad161. PMID: 37702430
49. Sarian G, Chalas C, **Le Teuff G**, Fayeche C, Dumas A, Demoor-Goldschmidt C, Fresneau B.
Post-treatment sperm cryopreservation practices in childhood and young adult cancer survivors. Reproductive Biomedicine Online. 2024 Feb;48(2):103573. doi: 10.1016/j.rbmo.2023.103573. Epub 2023 Oct 2. PMID: 38113762
50. Chapelle C, **Le Teuff G**, Zufferey PJ, Laporte S, Ollier E.
A framework to characterise the reproducibility of meta-analysis results with its application to direct oral anticoagulants in the acute treatment of venous thromboembolism. Research synthesis methods. 2024 Jan;15(1):117-129. doi: 10.1002/jrsm.1676. Epub 2023 Oct 17. PMID: 37846195
51. **Rousseau A, Michiels S, Simon-Tillaux N, Lolivier A, Bonastre J**, Planchard D, Barlesi F, Remon J, Lavaud P, Aldea M, Frelaut M, Le Pechoux C, Botticella A, Levy A, Gazzah A, **Foulon S**, Besse B.
Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. The Lancet Regional Health Europe. 2024 Jun 29:43:100970. doi: 10.1016/j.lanepe.2024.100970. eCollection 2024 Aug. PMID: 39040528

52. Renaud L, Wencel J, **Pagès A**, Al Jijakli A, Moatti H, Quero L, Camus V, Brice P. Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma. *Haematologica*. 2024 May 2. doi: 10.3324/haematol.2023.284689. Online ahead of print. PMID: 38695142
53. Valery S, **Simon-Tillaux N**, Devouassoux G, Bonniaud P, Beurnier A, Boudjemaa A, Chenivresse C, Bourdin A, Gauquelin L, Guillo S, Taillé C, Estellat C; RAMSES Study Group. Anti-IL-4R versus anti-IL-5/5R after anti-IL-5/5R failure in asthma: An emulated target trial. *The Journal of Allergy and Clinical Immunology*. 2024 Oct;154(4):922-932. doi: 10.1016/j.jaci.2024.05.023. Epub 2024 Jun 6. PMID: 38848878
54. Baudin E, Goichot B, Berruti A, Hadoux J, Moalla S, Laboureau S, Nölting S, de la Fouchardièrre C, Kienitz T, Deutschbein T, Zovato S, Amar L, Haissaguerre M, Timmers H, Niccoli P, Faggiano A, Angokai M, Lamartina L, Luca F, Cosentini D, Hahner S, Beuschlein F, Attard M, **Texier M**, Fassnacht M; ENDOCAN-COMETE; ENSAT Networks. Sunitinib for metastatic progressive pheochromocytomas and paragangliomas: results from FIRSTMAPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial. *Lancet*. 2024 Mar 16;403(10431):1061-1070. doi: 10.1016/S0140-6736(23)02554-0. Epub 2024 Feb 22. PMID: 38402886
55. Levy A, Morel D, **Texier M**, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, Racadot S, Supiot S, Magné N, Cyrille S, Louvel G, Massard C, Verlingue L, Bouquet F, Bustillos A, Bouarroudj L, Quevrin C, Clémenson C, Mondini M, Meziani L, Tselikas L, Bahleda R, Hollebecque A, Deutsch E. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer. *Molecular Cancer*. 2024 Mar 23;23(1):61. doi: 10.1186/s12943-024-01970-8. PMID: 38519913
56. Postel-Vinay S, Coves J, **Texier M**, Aldea M, Gazzah A, Dómine M, Planchard D, De Las Peñas R, Sala Gonzalez MA, Viteri S, Perez J, Ortega AL, Moran T, Camps C, Lopez-Martin A, Provencio M, Soria JC, Besse B, Massuti B, Rosell R. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial. *British Journal of Cancer*. 2024 Feb;130(3):417-424. doi: 10.1038/s41416-023-02514-5. Epub 2023 Dec 14. PMID: 38097741

57. Chargari C, Maury P, **Texier M**, Genestie C, Morice P, Bockel S, Gouy S, Ba M, Achkar S, Lux F, Tillement O, Dufort S, Duc GLE, Debeaumont O, Massard C, Maulard A, Porcel E, Bahleda R, Ammari S, Morel D, Espenel S, Pautier P, Robert C, Deutsch E.
Theragnostic Gadolinium-Based Nanoparticles Safely Augment X-ray Radiation Effects in Patients with Cervical Cancer. *ACS Nano*.
2024 Jul 2;18(26):16516-16529. doi: 10.1021/acsnano.3c12537.
Epub 2024 Jun 24. PMID: 38912600
58. Geoerger B, Bautista F, André N, Berlanga P, Gatz SA, Marshall LV, Rubino J, Archambaud B, Marchais A, Rubio-San-Simón A, Ducassou S, Zwaan CM, Casanova M, Nysom K, Pellegrino S, Hoog-Labouret N, Buzyn A, Blanc P, **Paoletti X**, Vassal G.
Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART. *European Journal of Cancer*. 2024 Sep;208:114201.
doi: 10.1016/j.ejca.2024.114201. Epub 2024 Jul 14. PMID: 39018630
59. Marchal A, Cirulli ET, Neveux I, Bellos E, Thwaites RS, Schiabor Barrett KM, Zhang Y, Nemes-Bokun I, Kalinova M, Catchpole A, Tangye SG, Spaan AN, Lack JB, Ghosn J, Burdet C, Gorochoy G, Tubach F, Hausfater P, COVID Human Genetic Effort; **COVIDeF Study Group**; French COVID Cohort Study Group; CoV-Contact Cohort; COVID-STORM Clinicians; Orchestra Working Group; Amsterdam UMC COVID-19 Biobank; NIAID-USUHS COVID Study Group; Dalgard CL, Zhang S-Y, Zhang Q, Chiu C, Fellay J, Grzymalski JJ, Sancho-Shimizu V, Abel L, Casanova J-L, Cobat A, Bolze A.
Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection. *HGG Advances*. 2024 Jul 18;5(3):100300.
doi: 10.1016/j.xhgg.2024.100300. Epub 2024 Apr 26. PMID: 38678364
60. Kedra J, Dieudé P, Giboin C, Marotte H, Salliot C, Schaefferbeke T, Perdriger A, Soubrier M, Morel J, Constantin A, Dernis E, Royant V, Salmon JH, Pham T, Gottenberg JE, Pertuiset E, Dougados M, Devauchelle-Pensec V, Gaudin P, Cormier G, Goupille P, Mariette X, Berenbaum F, Alcaix D, Rouidi SA, Berthelot JM, Monnier A, Piroth C, Lioté F, Goëb V, Gaujoux-Viala C, Chary-Valckenaere I, Hajage D, Tubach F, Fautrel B; **CRI-IMIDIATE clinical research network**.
Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission. *Arthritis & rheumatology*. 2024 Apr;76(4):541-552. doi: 10.1002/art.42752. Epub 2024 Jan 25.
PMID: 37942714

61. Louis Martin G, Petri C, Rozenberg J, **Simon N**, Hajage D, Kirchgesner J, Tubach F, Létinier L, Dechartres A.
A methodological review of the high-dimensional propensity score in comparative-effectiveness and safety-of-interventions research finds incomplete reporting relative to algorithm development and robustness.
Journal of Clinical Epidemiology. 2024 May;169:111305.
doi: 10.1016/j.jclinepi.2024.111305. Epub 2024 Feb 28. PMID: 38417583

62. Corbaux P, **Bayle A**, Besle S, Vinceneux A, Vanacker H, Ouali K, Hanvic B, Baldini C, Cassier PA, Terret C, Verlingue L.
Patients' selection and trial matching in early-phase oncology clinical trials.
Critical reviews in Oncology / Hematology. 2024 Apr;196:104307.
doi: 10.1016/j.critrevonc.2024.104307. Epub 2024 Feb 23. PMID: 38401694

63. Aghnatos L, Rofes GF, Sorli SC, Cestac P, **Pages A**, Eyvrard F.
[Covid-19: The impact of lockdown on the dispensing of hospital drugs to outpatients]. Santé Publique. 2024 Feb 23;35(6):39-51.
doi: 10.3917/spub.236.0039. PMID: 38388400

64. Borel C, Sun XS, Coutte A, Bera G, Sire C, Zanetta S, Alfonsi M, Janoray G, Chatellier T, Garcia-Ramirez M, Gherga E, Hammoud Y, Burgy M, Etienne-Selloum N, Pechery A, Girard-Calais MH, Velten M, **Pignon JP**, Wanneveich M, Bourhis J.
Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial. Radiotherapy and Oncology. 2024 Aug;197:110329.
doi: 10.1016/j.radonc.2024.110329. Epub 2024 May 19. PMID: 38768714

65. Di Meglio A, Havas J, Pagliuca M, Franzoi MA, Soldato D, Chiodi CK, Gillanders E, Dubuisson F, Camara-Clayette V, Pistilli B, Ribeiro J, Joly F, Cottu PH, Tredan O, Bertaut A, Ganz PA, Bower J, Partridge AH, Martin AL, Everhard S, Boyault S, Brutin S, André F, **Michiels S**, Pradon C, Vaz-Luis I.
A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance two years later. Annals of Oncology. 2024 Nov;35(11):1048-1060. doi: 10.1016/j.annonc.2024.07.728.
Epub 2024 Aug 2. PMID: 39098454

66. Sablin MP, Gestraud P, **Jonas SF**, Lamy C, Lacroix-Triki M, Bachelot T, Filleron T, Lacroix L, Tran-Dien A, Jézéquel P, Mauduit M, Barros Monteiro J, Jimenez M, **Michiels S**, Attignon V, Soubeyran I, Driouch K, Servant N, Le Tourneau C, Kamal M, André F, Bièche I.
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors.
2024 Oct;131(6):1060-1067. doi: 10.1038/s41416-024-02804-6.
Epub 2024 Aug 2. PMID: 39090361
67. Gatz SA, Harttrampf AC, **Brard C**, Bautista F, André N, Abbou S, Rubino J, Rondof W, Deloger M, Rübsam M, Marshall LV, Hübschmann D, **Nebchi S**, Aerts I, Thebaud E, De Carli E, Defachelles AS, **Paoletti X**, Godin R, Miah K, Mortimer PGS, Vassal G, Georger B.
Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial. *Clinical Cancer Research*. 2024 Feb 16;30(4):741-753.
doi: 10.1158/1078-0432.CCR-23-2959. PMID: 38051741
68. Bramuzzo M, **Giudici F**, Arrigo S, Lionetti P, Zuin G, Romano C, Graziano F, Faraci S, Alvisi P, Signa S, Scarallo L, Martellosi S, Di Leo G.
Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease. *Inflammatory bowel diseases*.
2024 Jan 5;30(1):20-28. doi: 10.1093/ibd/izad018. PMID: 36799567
69. Rajpar S, Ibrahim T, **Carmel A**, Merabet Z, Vielh P, **Foulon S**, Lesaunier F, Delva R, Rolland F, Priou F, Ferrero JM, Houédé N, Mourey L, Théodore C, Krakowski I, **Faivre L**, Habibian M, Culine S, Gravis G, Chauchereau A, Fizazi K.
The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials.
European Urology Oncology. 2024 Jul 20:S2588-9311(24)00173-1.
doi: 10.1016/j.euo.2024.06.015. Online ahead of print. PMID: 39034169
70. Ngo C, Cotteret S, **Deneche I**, Kfoury M, Chehab R, Tran-Dien A, Vibert J, Leary A, Gouy S, Maulard A, Morice P, Scoazec JY, Pautier P, Genestie C.
Uterine adenosarcoma: Clinical significance of histological classification and SNP array analysis. *Human Pathology*. 2024 Jun;148:14-22.
doi: 10.1016/j.humpath.2024.04.016. Epub 2024 Apr 28. PMID: 38688412

71. Fizazi K, **Le Teuff G**, Fléchon A, Pagliaro L, Mardiak J, Geoffrois L, Laguerre B, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Cancel M, Juzyna B, Reckova M, Naoun N, Logothetis C, Culine S.
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. *Journal of Clinical Oncology*. 2024 Oct;42(28):3270-3276.
doi: 10.1200/JCO.23.01960. Epub 2024 Aug 21. PMID: 39167741
72. Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Le Cesne A, Balleyguier C, **Archambaud B**, Duffaud F; French Sarcoma Group.
Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. *The New England journal of medicine*. 2024 Sep 5;391(9):789-799.
doi: 10.1056/NEJMoa2403394. PMID: 39231341
73. Gessain G, Anzali AA, Lerousseau M, Mulder K, Bied M, **Auperin A**, Stockholm D, Signolle N, Sassi F, Marques Da Costa ME, Marchais A, Sayadi A, Weidner D, Uderhardt S, Blampey Q, Nakkireddy SR, Broutin S, Dutertre CA, Busson P, Walter T, Marhic A, Moya-Plana A, Guerlain J, Breuskin I, Casiraghi O, Gorphe P, Classe M, Scoazec JY, Bleriot C, Ginhoux F.
Trem2-expressing multinucleated giant macrophages are a biomarker of good prognosis in head and neck squamous cell carcinoma. *Cancer Discovery*. 2024 Dec 2;14(12):2352-2366. doi: 10.1158/2159-8290.CD-24-0018
PMID: 39270324
74. Rigaud C, Forster VJ, Al-Tarrah H, Attarbaschi A, Bianchi V, Burke A, Burkhardt B, Colas C, Devalck C, Edwards M, Elitzur S, Garthe AK, Goldberg Y, Guerrini-Rousseau L, Horpaopan S, Januszkiewicz-Lewandowska D, Kabíčková E, Kratz CP, Loeffen J, Pérez-Alonso V, Pineda M, Minard-Colin V, Rueda D, Ruiz-Ponte C, Trinquand A, Uyttebroeck A, Wimmer K, **Auperin A**, Tabori U, Brugieres L.
Comprehensive analysis of constitutional mismatch repair deficiency-associated non-Hodgkin lymphomas in a global cohort. *Pediatric Blood & Cancer*. 2024 Dec;71(12):e31302. doi: 10.1002/pbc.31302. Epub 2024 Sep 19.
PMID: 39300701
75. Doublet S, **Pagès A**, Thomas ZA, Beraud-Chaulet G, Valery M, Naoun N, Canoui-Poitaine F, Nagera-Lazarovici C, Baldini C, Frélaud M.
Systemic treatment among frail older patients with cancer: An observational cohort. *Journal of Geriatric Oncology*. 2024 Dec 20;16(2):102177.
doi: 10.1016/j.jgo.2024.102177. Online ahead of print. PMID: 39708400

76. Cucherat M, Demarcq O, Chassany O, Le Jeune C, **Borget I**, Collignon C, Diebolt V, Feuilly M, Fiquet B, Leyrat C, Naudet F, Porcher R, Schmidely N, Simon T, Roustit M.
Methodological expectations for demonstration of health product effectiveness by observational studies. *Thérapie*. 2024 Dec 5:S0040-5957(24)00206-3.
doi: 10.1016/j.therap.2024.10.062. Online ahead of print. PMID: 39694790
77. Khalife-Hachem S, **Pages A**, Akoury E, Bonnet S, Birsén R, Busquet C, Contejean A, Danu A, De Botton S, De Charette M, Dumas PY, Jaccard A, Marfaing-Koka A, Willekens C, Deconinck E, Ghez D.
Venetoclax-Proteasome inhibitor-Dexamethasone for unfit patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. *Blood advances*.
2024 Dec 4:bloodadvances.2024014590.
doi: 10.1182/bloodadvances.2024014590. Online ahead of print. PMID: 39642332
78. Deschamps P, Wacheux M, Gosseye A, Morabito M, **Pagès A**, Lyne AM, Alfaro A, Rameau P, Imanci A, Chelbi R, Marchand V, Renneville A, Patnaik MM, Lapierre V, Badaoui B, Wagner-Ballon O, Berthon C, Braun T, Willekens C, Itzykson R, Fenaux P, Thépot S, Etienne G, Elvira-Matelot E, Porteu F, Droin N, Perié L, Laplane L, Solary E, Selimoglu-Buet D.
CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia. *The Journal of Clinical Investigation*.
2024 Sep 17;134(22):e180738. doi: 10.1172/JCI180738. PMID: 39545419
79. Nion N, Niérat M-C, Lavault S, **Simon-Tillaux N**, Guerder A, Blanchard P-Y, Morélot-Panzini C, Serresse L, Similowski T.
Empathetic solicitude attenuates the affective and sensory dimensions of CO₂-induced dyspnea: A randomized parallel arm experimental trial in healthy humans. *Psychophysiology*. 2024 Dec 3:e14740. doi: 10.1111/psyp.14740.
Online ahead of print. PMID: 39627961
80. Mathieu MC, Suciu V, **Tanguy ML**, Ben Romdhane NI, Moalla S, Harguem-Zayani S, Barbe R, Balleyguier C, Conversano A, Abbaci M.
Immediate Diagnosis of Breast Carcinoma on Core Needle Biopsy Using Ex Vivo Fluorescence Confocal Microscopy: Feasibility in a One-Stop Breast Clinic Workflow. *Life (Basel)*. 2024 Oct 28;14(11):1384. doi: 10.3390/life14111384.
PMID: 39598183

81. Dawi L, Belkouchi Y, Lawrance L, Gautier O, Ammari S, Vasseur D, Wirth F, Hadchiti J, Morer S, David C, Bidault F, Balleyguier C, Kind M, **Bayle A**, Belcaid L, Aldea M, Nicotra C, Geraud A, Sakkal M, Blanc-Durand F, Moog S, Mosele MF, Tagliamento M, Bernard-Tessier A, Verret B, Smolenschi C, Auger N, Gazzah A, Micol JB, Caron O, Hollebecque A, Lorient Y, Besse B, Lacroix L, Rouleau E, Ponce S, André F, Soria JC, Barlesi F, Muller S, Cournede PH, Talbot H, Italiano A, Lassau N.
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases. *Radiology*. 2024 Nov;313(2):e232674.
doi: 10.1148/radiol.232674. PMID: 39589242
82. Bossi A, **Foulon S**, Maldonado X, Sargos P, MacDermott R, Kelly P, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Salem N, Calabro F, Berdah JF, Hasbini A, Silva M, Boustani J, Ribault H, Fizazi K; PEACE-1 investigators. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. *Lancet*. 2024 Nov 23;404(10467):2065-2076. doi: 10.1016/S0140-6736(24)01865-8. PMID: 39580202
83. **Borget I**, Bendaib M, Poignant P, Rey L, Harty G, Chaudhari V, D'hooghe T, Schwarze JE, Cedrin Durnerin I, Roeder C, Grynberg M.
A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS). *Gynecologic and Obstetric Investigation*. 2024 Nov 19:1-15. doi: 10.1159/000542074. Online ahead of print.
PMID: 39561733
84. **Simon-Tillaux N**, Martin GL, Hajage D, Scheifer C, Beydon M, Dechartres A, Tubach F.
Conducting observational analyses with the target trial emulation approach: a methodological systematic review. *BMJ Open*. 2024 Nov 12;14(11):e086595.
doi: 10.1136/bmjopen-2024-086595. PMID: 39532374
85. Dixon-Douglas J, Virassamy B, Clarke K, Hun M, Luen SJ, Savas P, van Geelen CT, David S, Francis PA, Salgado R, **Michiels S**, Loi S.
Sustained lymphocyte decreases after treatment for early breast cancer. *NPJ breast cancer*. 2024 Oct 21;10(1):94. doi: 10.1038/s41523-024-00698-4. PMID: 39433772

86. **Bayle A**, Belcaid L, Cousin S, Trin K, Alame M, Rouleau E, Soubeyran I, Lacroix L, Blouin L, Vasseur D, Crombe A, Mathoulin-Pelissier S, Soria JC, Bellera C, Italiano A.
Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials. NPJ precision oncology. 2024 Oct 7;8(1):227.
doi: 10.1038/s41698-024-00685-9. PMID: 39375508

87. Vasseur D, Bigot L, Beshiri K, Flórez-Arango J, Facchinetti F, Hollebecque A, Tselikas L, Aldea M, Blanc-Durand F, Gazzah A, Planchard D, Lacroix L, Pata-Merci N, Nobre C, Da Silva A, Nicotra C, Ngo-Camus M, Braye F, Nikolaev SI, **Michiels S**, Jules-Clement G, Olausson KA, André F, Scoazec JY, Barlesi F, Ponce S, Soria JC, Besse B, Lorient Y, Friboulet L.
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development. Molecular cancer. 2024 Oct 4;23(1):221. doi: 10.1186/s12943-024-02134-4. PMID: 39363320

88. Michot JM, Dozio V, Rohmer J, Pommeret F, Roumier M, Yu H, Sklodowski K, Danlos FX, Ouali K, Kishazi E, Naigeon M, Griscelli F, Gachot B, Groh M, Bacciarello G, Stoclin A, Willekens C, Sakkal M, **Bayle A**, Zitvogel L, Silvin A, Soria JC, Barlesi F, Beeler K, André F, Vasse M, Chaput N, Ackermann F, Escher C, Marabelle A.
Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19. Journal of Proteome Research. 2024 Nov 1;23(11):5001-5015. doi: 10.1021/acs.jproteome.2c00422.
Epub 2024 Oct 1. PMID: 39352225

89. Soldato D; Vaz-Luis I, Di Meglio A, Jones LW, **Michiels S**.
Reply to S. Yang. Journal of Clinical Oncology. 2024 Dec 20;42(36):4354-4355.
doi: 10.1200/JCO-24-01768. Epub 2024 Sep 20. PMID: 39303199

90. Valéry M, **Tanguy ML**, Gelli M, Smolenschi C, Hollebecque A, Boilève A, de Sevilla EF, Tselikas L, Bonnet B, Goéré D, Taïeb J, Boige V, Ducreux M, Malka D.
Oxaliplatin-induced peripheral neuropathy with hepatic arterial versus intravenous infusion in metastatic colorectal cancer. Supportive Care in Cancer. 2024 Sep 16;32(10):660. doi: 10.1007/s00520-024-08807-6. PMID: 39283505

91. Cartron G, Thieblemont C, **Borget I**, Rioufol C, Berthet M, Portal C, Baujat C, Alaoui E, Baffert S, Lacroix D, Bories P, Yakoub-Agha I, Houot R.
[Real-life evaluation of the care pathway of patients eligible for axicabtagene ciloleucel treatment: Analysis of a multicenter retrospective cohort (IMPA-CT study)]. [Article in French]. Bulletin du Cancer. 2024 2024 Nov;111(11):1020-1029.
doi: 10.1016/j.bulcan.2024.07.010. Epub 2024 Sep 11. PMID: 39266425

92. Facchinetti F, Lorient Y, Brayé F, Vasseur D, Bahleda R, Bigot L, Barbé R, Nobre C, Combarel D, **Michiels S**, Italiano A, Smolenschi C, Tselikas L, Scoazec JY, Ponce-Aix S, Besse B, André F, Olausson KA, Hollebecque A, Friboulet L. Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies. *Clinical Cancer Research*. 2024 Nov 1;30(21):4943-4956. doi: 10.1158/1078-0432.CCR-24-1834. PMID: 39226398
93. Westphalen CB, Martins-Branco D, Beal JR, Cardone C, Coleman N, Schram AM, Halabi S, **Michiels S**, Yap C, André F, Bibeau F, Curigliano G, Garralda E, Kummar S, Kurzrock R, Limaye S, Loges S, Marabelle A, Marchió C, Mateo J, Rodon J, Spanic T, Pentheroudakis G, Subbiah V. The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development. *Annals of Oncology*. 2024 Nov;35(11):936-953. doi: 10.1016/j.annonc.2024.07.730. Epub 2024 Aug 25. PMID: 39187421
94. Franzoi MA, **Pages A**, Papageorgiou L, Di Meglio A, Laparra A, Martin E, Barbier A, Renvoise N, Arvis J, Scotte F, Vaz-Luis I. Evaluating the Implementation of Integrated Proactive Supportive Care Pathways in Oncology: Master Protocol for a Cohort Study. *JMIR research protocols*. 2024 Aug 26;13:e52841. doi: 10.2196/52841. PMID: 39186774
95. Dourthe ME, **Auperin A**, Rigaud C, Barbat M, Bonneau J, Buchbinder N, Couec ML, Dartigues P, Ducassou S, Garnier N, Haouy S, Jonca B, Jourdain A, Leruste A, Molina T, Montravers F, Pasquet M, Phulpin A, Poirée M, Simonin M, Spiegel A, Verschuur A, Leblanc T, Landman-Parker J, Patte C, Minard-Colin V. Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with FAB/LMB-based chemotherapy regimen with rituximab. *Haematologica*. 2024 Nov 1;109(11):3790-3794. doi: 10.3324/haematol.2024.285403 PMID: 38988265
96. Horgan D, Pesapane F, Van der Buckle M, de Maria R, Dube F, Singh J, Ługowska I, **Bayle A**, Hofman P, Malapelle U, Hills T, Capoluongo ED, Subbiah V. From theory to practice: Implementing next-generation sequencing and public health genomics in healthcare systems. *Critical Reviews in Oncology/Hematology*. 2024 Sep;201:104433. doi: 10.1016/j.critrevonc.2024.104433. Epub 2024 Jun 30. PMID: 38955310

97. Peimani M, Stewart AL, **Ghodssi-Ghassemabadi** R, Nasli-Esfahani E, Ostovar A.
The moderating role of e-health literacy and patient-physician communication in the relationship between online diabetes information-seeking behavior and self-care practices among individuals with type 2 diabetes. BMC primary care. 2024 Dec 30;25(1):442. doi: 10.1186/s12875-024-02695-9. PMID: 39736551
98. **Benkirane H**, Vakalopoulou M, **Michiels S**, Cournède P-H, Lotter W. Counterfactual Analysis for Digital Histopathology Slides Using Human Interpretable Features. Conference Medical Imaging with Deep Learning.
99. **Hill, C**.
Le problème de santé publique de la consommation d'alcool va bien au-delà des problèmes de dépendance et de binge drinking. Alcoologie et Addictologie. 2024 Tome 44, n°3
100. Saucier E, Bougeard G, Gomez-Mascard A, Schramm C, **Abbas R**, Berlanga P, Briandet C, Castex MP, Corradini N, Coze C, Guerrini-Rousseau L, Guinebretière JM, Khneisser P, Lervat C, Mansuy L, Marec-Berard P, Marie-Cardine A, Mascard E, Saumet L, Tabone MD, Winter S, Frebourg T, Gaspar N, Brugieres L.
Li-Fraumeni-associated osteosarcomas: The French experience.
Pediatric blood & cancer. 2024 Dec;71(12):e31362. doi: 10.1002/pbc.31362. Epub 2024 Oct 10. PMID: 39387369
101. Atsou K, **Auperin A**, Guigay J, Salas S, Benzekry S.
Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma. CPT: pharmacometrics & systems pharmacology. 2024 Dec 25. doi: 10.1002/psp4.13294. Online ahead of print. PMID: 39722558

